Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months Post published:November 4, 2025 Post category:Analysis/News/Pα+
The Psychedelic News Feed: October 27 – November 02, 2025 Post published:November 4, 2025 Post category:Psychedelic News Feed Archive
Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M Post published:October 31, 2025 Post category:Psychedelic Bulletin/Pα+
The Psychedelic News Feed: October 20 – 26, 2025 Post published:October 27, 2025 Post category:Psychedelic News Feed Archive
Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed Post published:October 24, 2025 Post category:Psychedelic Bulletin/Pα+
Q3’25 Investor Survey: What are Investors Most Concerned About? Post published:October 23, 2025 Post category:Analysis/News/Pα+
A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda Post published:October 22, 2025 Post category:Interviews
Q3’25 Survey: What are Psychedelics Investors Excited About? Post published:October 21, 2025 Post category:Analysis/News/Pα+
The Psychedelic News Feed: October 13 – 19, 2025 Post published:October 20, 2025 Post category:Psychedelic News Feed Archive